Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience has signed a term sheet with Kotler Investment Ltd. to establish a joint venture aimed at expanding the market for their ROMEGA® products in China and Southeast Asia, one of the world’s largest Omega-3 markets. This partnership is intended to capitalize on the significant growth potential in these regions, following a successful sales record in China, and aims to strengthen the ROMEGA® brand and extend distribution. The company anticipates continued growth and positive cash flow in the coming years, supported by a recent financing solution.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech firm focusing on developing and commercializing pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. They are working on HRO350, an oral drug candidate for mild-to-moderate psoriasis, and offer nutraceuticals globally under the ROMEGA® brand.
YTD Price Performance: 84.96%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €7.33M
See more data about 9TD stock on TipRanks’ Stock Analysis page.